Heparanase Stimulates Chondrogenesis and Is Up-Regulated in Human Ectopic Cartilage A Mechanism Possibly Involved in Hereditary Multiple Exostoses

被引:39
作者
Huegel, Julianne [1 ]
Enomoto-Iwamoto, Motomi [1 ]
Sgariglia, Federica [1 ]
Koyama, Eiki [1 ]
Pacifici, Maurizio [1 ]
机构
[1] Childrens Hosp Philadelphia, Div Orthopaed Surg, Translat Res Program Pediat Orthopaed, Philadelphia, PA 19104 USA
关键词
MAMMALIAN HEPARANASE; CANCER METASTASIS; CELL-ADHESION; MOUSE MODEL; SULFATE; EXT1; HETEROZYGOSITY; PHENOTYPE; GROWTH; DIFFERENTIATION;
D O I
10.1016/j.ajpath.2015.02.014
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Hereditary multiple exostoses is a pediatric skeletal disorder characterized by benign cartilaginous tumors called exostoses that form next to growing skeletal elements. Hereditary multiple exostoses patients carry heterozygous mutations in the heparan sulfate (HS)-synthesizing enzymes EXT1 or EXT2, but studies suggest that EXT haploinsufficiency and ensuing partial HS deficiency are insufficient for exostosis formation. Searching for additional pathways, we analyzed presence and distribution of heparanase in human exostoses. Heparanase was readily detectable in most chondrocytes, particularly in cell clusters. In control growth plates from unaffected persons, however, heparanase was detectable only in hypertrophic zone. Treatment of mouse embryo Limb mesenchymal micromass cultures with exogenous heparanase greatly stimulated chondrogenesis and bone morphogenetic protein signaling as revealed by Smad1/5/8 phosphorylation. It also stimulated cell migration and proliferation. Interfering with HS function both with the chemical antagonist Surfen or treatment with bacterial heparitinase up-regulated endogenous heparanase gene expression, suggesting a counterintuitive feedback mechanism that would result in further HS reduction and increased signaling. Thus, we tested a potent heparanase inhibitor (SST0001), which strongly inhibited chondrogenesis. Our data clearly indicate that heparanase is able to stimulate chondrogenesis, bone morphogenetic protein signaling, cell migration, and cell proliferation in chondrogenic cells. These properties may allow heparanase to play a role in exostosis genesis and pathogenesis, thus making it a conceivable therapeutic target in hereditary multiple exostoses.
引用
收藏
页码:1676 / 1685
页数:10
相关论文
共 50 条
[1]   Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment [J].
Abboud-Jarrous, Ghada ;
Atzmon, Ruth ;
Peretz, Tamar ;
Palermo, Carmela ;
Gadea, Bedrick B. ;
Joyce, Johanna A. ;
Vlodavsky, Israel .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (26) :18167-18176
[2]   POSITION-RELATED CAPACITY FOR DIFFERENTIATION OF LIMB MESENCHYME IN CELL-CULTURE [J].
AHRENS, PB ;
SOLURSH, M ;
REITER, RS ;
SINGLEY, CT .
DEVELOPMENTAL BIOLOGY, 1979, 69 (02) :436-450
[3]   Functions of cell surface heparan sulfate proteoglycans [J].
Bernfield, M ;
Götte, M ;
Park, PW ;
Reizes, O ;
Fitzgerald, ML ;
Lincecum, J ;
Zako, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1999, 68 :729-777
[4]   EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas [J].
Bovée, JVMG ;
Cleton-Jansen, AM ;
Wuyts, W ;
Caethoven, G ;
Taminiau, AHM ;
Bakker, E ;
Van Hul, W ;
Cornelisse, CJ ;
Hogendoorn, PCW .
AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (03) :689-698
[5]   Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation [J].
Brown, A. J. ;
Alicknavitch, M. ;
D'Souza, S. S. ;
Daikoku, T. ;
Kirn-Safran, C. B. ;
Marchetti, D. ;
Carson, D. D. ;
Farach-Carson, M. C. .
BONE, 2008, 43 (04) :689-699
[6]   Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models [J].
Cassinelli, G. ;
Lanzi, C. ;
Tortoreto, M. ;
Cominetti, D. ;
Petrangolini, G. ;
Favini, E. ;
Zaffaroni, N. ;
Pisano, C. ;
Penco, S. ;
Vlodavsky, I. ;
Zunino, F. .
BIOCHEMICAL PHARMACOLOGY, 2013, 85 (10) :1424-1432
[7]   Non-Anticoagulant Heparins and Inhibition of Cancer [J].
Casu, Benito ;
Vlodavsky, Israel ;
Sanderson, Ralph D. .
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2007, 36 (3-4) :195-203
[8]   Heparanase as mediator of angiogenesis: mode of action [J].
Elkin, M ;
Ilan, N ;
Ishai-Michaeli, R ;
Friedmann, Y ;
Papo, O ;
Pecker, I ;
Vlodavsky, I .
FASEB JOURNAL, 2001, 15 (07) :1661-+
[9]   Order out of chaos: Assembly of ligand binding sites in heparan sulfate [J].
Esko, JD ;
Selleck, SB .
ANNUAL REVIEW OF BIOCHEMISTRY, 2002, 71 :435-471
[10]   Human platelet heparanase: purification, characterization and catalytic activity [J].
Freeman, C ;
Parish, CR .
BIOCHEMICAL JOURNAL, 1998, 330 :1341-1350